Graeme Martin is President and CEO of Takeda Ventures, Inc (TVI), the strategic venture investment arm of Takeda Pharmaceutical Company, Ltd. Since joining Takeda in 2003, Dr Martin has overseen investment into 21 early and mid-stage biotechnology companies which have produced strategic relationships with Takeda R&D operations. One company, Envoy Therapeutics, was acquired by Takeda in 2012. During more than 35 years in multinational Pharmaceutical and Biotech R&D, both in Europe and the USA, Dr Martin has worked on three novel drug IND candidates, including zolmitriptan, an acute treatment for migraine now marketed worldwide under the brand name Zomig. He is the author of more than 85 peer-reviewed publications and book chapters. He received his Bachelor of Science degree in Pharmacology from the University of Bath, UK and his doctorate from University College, London, UK.